Neurizon Therapeutics Expands Shareholding Amid ALS Treatment Push

Pharmaust Limited (AU:NUZ) has released an update.

Neurizon Therapeutics Limited has issued 400,000 fully paid ordinary shares following the exercise of unlisted options, priced at $0.10 each. This move, part of their broader strategy to accelerate treatments for ALS and other neurodegenerative diseases, underscores Neurizon’s commitment to advancing its lead drug candidate NUZ-001. The company remains compliant with relevant corporate regulations, ensuring transparency in its financial operations.

For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.